Haploidentical Stem Cell Transplantation (SCT) Using Flamsa Regimen As Salvage Chemotherapy
Authors: Yuksel Meltem Kurt , Gokmen Ayla , Ozcan Muhit , Arslan Onder , Ilhan Osman , Ozbek Devrim , Okcu Mevlude Kurdal , Koktas Ozlem 
Published: October 2019

Haploidentical donors are alternative stem cell sources for the patients without matched related and unrelated donors. Finding a full match unrelated donor takes at least 6 months. Most of the patients who have advanced acute leukemia die during this period. Unfortunately, they also loose the chance of haploidentical stem cell transplantation (SCT).

Aim: To report the outcome of six patients whom underwent haploidentical stem cell transplantation using FLAMSA regimen as initial reduction of leukemic burden.

Patients and Treatment: There were six patients (F/M: 3/3) who admitted to transplantation unit between November 2012 and December 2013. Table 1 shows the characteristics of patients. Patients received fludarabine 30mg/m2, ARA-C 2gm/m2, Amsacrine 100 mg/m2 (FLAMSA) consequently 4 days before the intiation of conditioning protocol. According to the conditioning protocol number of the rest days changed (Table 2). For transplantation G-CSF mobilized peripheral blood stem cells were used. No graft manipulation was performed, 5x10e6 CD34+ cells/kg were requested. Graft versus host disease (GVHD) prophylaxis: Cyclophosphamide 50mg/kg/day (+3,+4), Tacrolimus 0.03 mg/kg/day +5 and MMF 3x15mg/kg +6 was started. In the absence of GVHD, MMF was discontinued by day +30, tacrolimus was tapered from day +60 to +100.

Results: All of the patients had active diseases. Three of the six patients died during conditioning. Transplantation related mortality (TRM) was 50%. The other three patients were alive on the day 100. Overall survive (OS) on day 100 was %50. Two patients (22%) lived beyond 6 months. Of these two, one of them has completed the first year (16%) and is still alive without GVHD or disease relaps. Outcome of the patients are shown in Table 2.

Discussion: The patient number is so restricted to draw any conclusions from this report but we know that Allogeneic SCT is the most effective treatment for a variety of hematologic malignancies. The current data suggest that the chosen sequential strategy of intensive chemotherapy followed after a few days of rest by allogeneic SCT has encourging results. Combining this modality with haploidentical transplantation may represent a step forward in the treatment of refractory hematologic malignancies.

Table1: Patients’ and donors’ characteristics Patient no Gender Patient Age Diagnosis Tx no PRA Donor Donor age 1 M 37 ALL 1st Neg Brother 44 2 F 47 ALL 1st Neg Son 23 3 F 44 AML 1st Neg Son 22 4 M 41 AML 3rd(2MSD) Neg Mother 65 5 F 26 AML 2nd(1MUD) Neg Mother 54 6 F 46 ALL 2nd(1MSD) Neg Sister 53

M: Male F: Female ALL: Acute lymphoblastic leukemia, AML: Acute myeloblastic leukemia, Tx no: Number of transplantation, PRA: Panel Reactive Antibody, Neg: Negative

MS:Match Sibling Donor, MUD Match Unrelated Donor)

Abstract 5925 Table 2: Patients’ outcome Patient no Conditioning regimen Rest day (s) after FLAMSA Engraftment PLT 20/ NEU0.5 Chimerism on day 30 Engraftment failure Reinfusion of peripheral blood CD34+ GVHD Grade 3-4 Comorbid condition Status after SCT 1 MEL50mg/m2/day (-5,-4) TBI Gy (-3,-2,-1) -6 Yes Full Yes +105.day Yes No Exitus +210 day GVHD 2 MEL50mg/m2/day (-5,-4) TBI 4Gy(-3,-2,-1) -6 Yes Full No No No No Alive +390day 3 MEL 200mg/m2 (-1) -3,-2 No - - - - IPA Exitus+14day Gram negative septicemia 4 BU 3.2mg/kg/day (-5,-4,-3,-2) MEL 140mg/m2/day (-1) -9,-8,-7,-6 No - - - - IPA Exitus+12day Candidemi 5 MEL 200mg/m2 (-1) -3,-2 Yes Full Yes +125day No IPA Alive +240 day 6 BU 3.2mg/kg/day (-5,-4,-3,-2) MEL 140mg/m2/day (-1) -9,-8,-7,-6 No - - NA Panniculitis IPA Exitus day 0

BU: Busulfan, Mel: Melfelan, TBI: Total Body Irradiation, PLT 20: Platelet > 20.000 NEU 0.5: Neutrophil>500, GVHD: Graft versus Host Disease, IPA: Invasive Pulmonary Aspergillozis,

Disclosures

No relevant conflicts of interest to declare.